{
    "clinical_study": {
        "@rank": "132895", 
        "acronym": "GLOBE", 
        "arm_group": [
            {
                "arm_group_label": "vildagliptin and metformin", 
                "arm_group_type": "Active Comparator", 
                "description": "Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks"
            }, 
            {
                "arm_group_label": "glimepiride and metformin", 
                "arm_group_type": "Active Comparator", 
                "description": "Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the effect of a fixed dose combination of\n      vildagliptin plus metformin versus combination therapy of glimepiride plus metformin in\n      glycemic variability in patients with type 2 diabetes who have not achieved adequate control\n      of their disease prior to treatment with metformin monotherapy in optimal  doses."
        }, 
        "brief_title": "Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Type 2 Diabetes", 
            "Hypoglycemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Hypoglycemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HbA1c between 8%-10.5% in stable metformin dose (>1500 mg/day), four weeks prior\n             visit 1\n\n        Exclusion Criteria:\n\n          -  Use of other antidiabetic oral therapy during the last 3 months (sulphonylurea,\n             glitazones, GLP-1 analogues, DPP-4 inhibitors), except metformin\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02007278", 
            "org_study_id": "CLAF237ACO01"
        }, 
        "intervention": [
            {
                "arm_group_label": "vildagliptin and metformin", 
                "description": "vildagliptin and metformin combination therapy as 50mg/850mg bid or 50mg/1000mg bid", 
                "intervention_name": "vildagliptin and metformin (combination)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "glimepiride and metformin", 
                "intervention_name": "glimepiride", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "glimepiride and metformin", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glimepiride", 
                "Vildagliptin", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "diabetes", 
            "hypoglycemia", 
            "glycemic variability", 
            "vildagliptin", 
            "glimepiride"
        ], 
        "lastchanged_date": "March 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Medell\u00edn", 
                        "country": "Colombia", 
                        "state": "Antioquia"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manizales", 
                        "country": "Colombia", 
                        "state": "Caldas", 
                        "zip": "1700"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manizales", 
                        "country": "Colombia", 
                        "state": "Caldas", 
                        "zip": "1700"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bogot\u00e1", 
                        "country": "Colombia", 
                        "state": "Cundinamarca"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ch\u00eda", 
                        "country": "Colombia", 
                        "state": "Cundinamarca", 
                        "zip": "11001000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cali", 
                        "country": "Colombia", 
                        "state": "Valle del Cauca", 
                        "zip": "001"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Colombia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Glycemic Excursions in Type 2 Diabetic Patients Treated With Vildagliptin and Metformin (GalvusMet) Versus Glimepiride and Metformin", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "National Institute of Food and Drug Monitoring (INVIMA): Colombia", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Mean Amplitude of Glycemic Excursions (MAGE) , which determine the average blood glucose excursions either above or below a value of one standard deviation of the average value of glucose in a given day. MAGE is calculated from the data of continuous tissue glucose monitoring obtained during the measurement period.", 
            "measure": "glycemic variability measured by Mean Amplitude of Average Glucose Excursions (MAGE)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02007278"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Continuous Overlapping Net Glycemic Action (CONGA)  which assesses intraday glycemic variability by calculating the difference between values at different intervals, adjusted according to requirements with the advantage of being highly reproducible.", 
                "measure": "glycemic variability measured by Continuous Overlapping Net Glycemic Action (CONGA)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Percentage of patients who achieve a decrease equal to or greater than 0.3% in value of HbA1c at week 12 of treatment in comparison to HbA1c value at screening visit", 
                "safety_issue": "No", 
                "time_frame": "Screening visit , 12 weeks of treatment"
            }, 
            {
                "measure": "Percentage of reduction achieved in the mean HbA1c at week 12 of treatment in comparison to HbA1c at screening visit", 
                "safety_issue": "No", 
                "time_frame": "Screening visit , 12 weeks of treatment"
            }, 
            {
                "measure": "Degree of correlation between MAGE value and hypoglycemia incidence", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Hypoglycemia defined as Glycemia < 70 mg/dl", 
                "measure": "percentage of patients with incidence of hypoglycemia", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Total standard deviation (TSD) or standard deviation of all values of a given measurement period, which has the advantage of being able to include all measured values on a given time period (even several days) through a common and simple statistical concept.", 
                "measure": "Glycemic variability measured by Total Standard Deviation (TSD)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Number of patients with adverse events, serious adverse events and death", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}